



NPCA, Clinical Effectiveness Unit

Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: NPCA@rcseng.ac.uk T: 020 7869 6065 X @NPCA_uk

NPCA Newsletter, November 2024

The NPCA is now part of NATCAN (National Cancer Audit Collaborating Centre). As you are on the NPCA mailing list, you will **now also be included in the NATCAN newsletter mailing list**. If you do not wish to receive NATCAN newsletters, there will be the option to opt out.

Fourth quarterly report published 14.11.24

On 14th November 2024, the NPCA published their <u>fourth quarterly audit report</u> for provider trusts in England for patients diagnosed with prostate cancer in England between 1st April 2021 and 31st March 2024. As previously, data completeness results for each Trust for ethnicity, performance status, PSA, TNM and Gleason Score are available for each provider Trust in England, as well as summary statistics for England and broken down by Cancer Alliance (see Table, right).

Results for the performance indicator "Proportion of patients undergoing an emergency readmission 90 days following radical prostatectomy" are also available.

				le with		Proportion of people
Cancer Alliance	ethnicity recorded (%)	Gleason score recorded (%)	performance status recorded (%)		TNM staging recorded (%)	who had an emergency readmission within 90 days of radical prostate cancer surgery* (%)
Cheshire and Merseyside	97%	74%	88%	78%	86%	12%
East Midlands	88%	74%	48%	52%	63%	17%
East of England	92%	83%	68%	64%	71%	9%
Greater Manchester	96%	83%	81%	61%	82%	8%
Humber and North Yorkshire	85%	76%	62%	80%	79%	8%
Kent and Medway	84%	82%	83%	45%	69%	20%
Lancashire and South Cumbria	94%	82%	90%	76%	85%	15%
North Central London	92%	81%	49%	26%	64%	8%
North East London	97%	72%	23%	63%	74%	N/A**
Northern	94%	79%	80%	70%	69%	17%
Peninsula	94%	68%	75%	61%	71%	11%
RM Partners	91%	82%	61%	31%	77%	8%
Somerset, Wiltshire, Avon and Gloucestershire	85%	75%	41%	33%	58%	11%
South East London	85%	80%	58%	63%	67%	7%
South Yorkshire and Bassetlaw	94%	85%	55%	38%	62%	17%
Surrey and Sussex	84%	79%	81%	87%	81%	8%
Thames Valley	83%	85%	68%	77%	74%	16%
Wessex	83%	68%	86%	69%	84%	12%
West Midlands	91%	82%	84%	62%	77%	17%
West Yorkshire and Harrogate	96%	81%	86%	56%	78%	18%

*Adjusted for the distribution of age, co-morbidity (Charlson score), prostate cancer stage (I-IV) and deprivation (IMD) within the Cancer Alliant **The Trusts within the North East London Cancer Alliance didn't have a record of conducting any radical prostate cancer surgeries.

This report introduces the patient characteristics **age and deprivation**.

Second State of the Nation



Preparation for the NPCA's second State of the Nation report is well underway with an expected publication date of **Thursday 9th January 2025.**

Watch this space!

Team news

On 1st October 2024, **Arjun Nathan** (re)joined the NPCA Team to begin his NIHR-funded PhD fellowship looking at **malignant ureteric obstruction** in locally advanced and metastatic prostate cancer.



Welcome (back) Arjun!



NATCAN National Cancer Audit Collaborating Centre

This email was sent to you by NPCA, part of the National Cancer Audit Collaborating Centre (NATCAN) based at the Royal College of Surgeons of England. To ensure continued receipt of our emails please add us to your address book or safe list. In accordance with the General Data Protection Regulation (GDPR), NATCAN is committed to protecting your privacy. If you wish to know more please access our privacy policy. If you no longer wish to receive any messages please unsubscribe. © RCS 2023, Registered Charity No. 212808

BUG and BAUS

Oncology presentations





Dr Alison Tree, NPCA Clinical Lead Oncology, presented unpublished results from the second State of the Nation at the **British Uro-oncology Group meeting in Belfast** on Saturday 7th September 2024.

Mr Noel Clarke, NPCA Clinical Lead Urology, also presented similar findings at the **British Association of Urological Surgeons Oncology Section meeting in Nottingham** on Friday 15th November 2024.